According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “
AIMT has been the topic of several other reports. ValuEngine upgraded shares of Vistra Energy from a “hold” rating to a “buy” rating in a research report on Wednesday, July 3rd. Cantor Fitzgerald restated a “buy” rating and set a $27.00 target price on shares of Spero Therapeutics in a research report on Thursday, May 9th. BidaskClub upgraded shares of Zillow Group from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 2nd. Credit Suisse Group decreased their target price on shares of Athene from $67.00 to $57.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 21st. Finally, Wedbush restated a “buy” rating and set a $36.00 target price on shares of Allena Pharmaceuticals in a research report on Tuesday, July 2nd. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Aimmune Therapeutics presently has a consensus rating of “Hold” and an average target price of $46.43.
Shares of AIMT traded down $1.38 during midday trading on Tuesday, hitting $18.51. 115,076 shares of the company traded hands, compared to its average volume of 559,136. The firm has a 50 day simple moving average of $20.23. Aimmune Therapeutics has a 52 week low of $19.25 and a 52 week high of $36.12. The stock has a market cap of $1.31 billion, a PE ratio of -5.04 and a beta of -0.06. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.65 and a current ratio of 7.65.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.07. On average, equities analysts anticipate that Aimmune Therapeutics will post -3.77 EPS for the current year.
A number of institutional investors have recently bought and sold shares of AIMT. Cable Hill Partners LLC raised its position in Aimmune Therapeutics by 81.7% in the 1st quarter. Cable Hill Partners LLC now owns 1,112 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 500 shares during the period. Manchester Capital Management LLC purchased a new stake in Aimmune Therapeutics in the 1st quarter worth about $27,000. Pearl River Capital LLC purchased a new stake in Aimmune Therapeutics in the 1st quarter worth about $28,000. Marshall Wace North America L.P. purchased a new stake in Aimmune Therapeutics in the 1st quarter worth about $32,000. Finally, Advisor Group Inc. raised its position in Aimmune Therapeutics by 84.6% in the 4th quarter. Advisor Group Inc. now owns 1,737 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 796 shares during the period. 76.12% of the stock is currently owned by institutional investors.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Recommended Story: Earnings Per Share
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.